FDA Approved: DOCETAXEL — Supplemental Application (Sanofi-Aventis U.S. LLC)

View source ↗

Summary

The FDA approved a supplemental application for Docetaxel (Sanofi-Aventis U.S. LLC), indicating an approved modification to its labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

SUPPL AP for DOCETAXEL (DOCETAXEL)